ImmunityBio (IBRX) Other Operating Expenses (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Other Operating Expenses of -$236.6 million for Q1 2026, down 455.69% year-over-year from $66.5 million in Q1 2025, and down 123787.43% quarter-over-quarter from -$191000.0 in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Other Operating Expenses (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Other Operating Expenses for 9 consecutive years, with -$236.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses fell 455.69% year-over-year to -$236.6 million; the TTM figure through Mar 2026 stood at -$236.8 million (down 26708.54% YoY), while the FY2025 annual figure was -$42.8 million, down 198.39% from the prior year.
- Other Operating Expenses retreated to -$236.6 million in Q1 2026 per IBRX's latest filing, from -$191000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $43.5 million in Q4 2024 and bottomed at -$236.6 million in Q1 2026.
- Historically, Other Operating Expenses has averaged -$30.2 million across 4 years, with a median of -$1.2 million in 2025.
- Annual changes were most pronounced in 2024 — Other Operating Expenses surged 217.64% — and 2026, when it tumbled 455.69%.
- ImmunityBio's Other Operating Expenses stood at -$37.0 million in 2023, then soared by 217.64% to $43.5 million in 2024, then plunged by 100.44% to -$191000.0 in 2025, then slumped by 123787.43% to -$236.6 million in 2026.
- Business Quant data shows IBRX's Other Operating Expenses at -$236.6 million in Q1 2026, -$191000.0 in Q4 2025, and -$1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | ImmunityBio | 8.47 Bn | 8.12 Bn | 50.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 298,000.00 |
| Mar 31, 2026 | 238,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Dec 31, 2023 | 886,000.00 |
| Dec 31, 2022 | 681,000.00 |
| Dec 31, 2020 | -36.33 Mn |
| Sep 30, 2020 | 10.66 Mn |
| Dec 31, 2019 | -90.60 Mn |
| Dec 31, 2016 | 7.44 Mn |
| Dec 31, 2015 | 2.10 Mn |
| Mar 31, 2014 | 120,000.00 |